MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting

MRD as an early endpoint for accelerated approval: a success storyПодробнее

April 12, 2024 Meeting of the Oncologic Drugs Advisory Committee (ODAC)Подробнее

What does the FDA approval of MRD testing for myeloma mean for patients and drug development?Подробнее

Accelerating drug approval with better metrics in myelomaПодробнее

The association between MRD and PFS in myelomaПодробнее

Standardizing MRD techniques after FDA approval as a surrogate endpoint in myeloma trialsПодробнее

Using MRD Status as an Endpoint for Drug Approval with Dr. Manni MohyuddinПодробнее

Using MRD to accelerate drug approval in multiple myelomaПодробнее

Should MRD Status be used as a good endpoint for drug approval?Подробнее

Looking forward to the Miami Myeloma MRD Virtual Meeting 2024Подробнее

The possibility of using MRD as a surrogate endpoint for PFS and OS in myeloma clinical trialsПодробнее

How can MRD negativity be used as an endpoint in clinical trials?Подробнее

Using MRD as an endpoint in clinical trialsПодробнее

MRD testing is a reliable endpoint for the assessment of deep responses in myeloma clinical trialsПодробнее

Is MRD Negativity the Goal of Myeloma Treatment?Подробнее

The potential of MRD-adapted treatment in multiple myelomaПодробнее

The value of MRD as an early endpoint in multiple myeloma clinical trialsПодробнее

The importance of MRD in multiple myeloma in guiding treatment decisions & access to therapiesПодробнее

MRD in multiple myeloma: prognosis, a clinical trial endpoint, and guiding treatment decisionsПодробнее